207 related articles for article (PubMed ID: 25988317)
1. Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial.
Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB
Sci Rep; 2015 May; 5():10140. PubMed ID: 25988317
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment.
Lee SY; Chen SL; Chang YH; Chu CH; Chen SH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB
Int J Neuropsychopharmacol; 2015 Feb; 18(7):pyv008. PubMed ID: 25716777
[TBL] [Abstract][Full Text] [Related]
3. Correlation between interleukin-6 levels and methadone maintenance therapy outcomes.
Lu RB; Wang TY; Lee SY; Chen SL; Chang YH; See Chen P; Lin SH; Chu CH; Huang SY; Tzeng NS; Lee IH; Chin Chen K; Kuang Yang Y; Chen P; Chen SH; Hong JS
Drug Alcohol Depend; 2019 Nov; 204():107516. PubMed ID: 31513981
[TBL] [Abstract][Full Text] [Related]
4. Correlation of cytokines, BDNF levels, and memory function in patients with opioid use disorder undergoing methadone maintenance treatment.
Wang TY; Lee SY; Chang YH; Chen SL; Chen PS; Chu CH; Huang SY; Tzeng NS; Lee IH; Chen KC; Yang YK; Chen SH; Hong JS; Lu RB
Drug Alcohol Depend; 2018 Oct; 191():6-13. PubMed ID: 30071446
[TBL] [Abstract][Full Text] [Related]
5. Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study.
Lee SY; Wang TY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Chen KC; Yang YK; Hong JS; Lu RB
Alcohol Clin Exp Res; 2018 Jun; 42(6):1044-1050. PubMed ID: 29656414
[TBL] [Abstract][Full Text] [Related]
6. Dextromethorphan attenuated inflammation and combined opioid use in humans undergoing methadone maintenance treatment.
Chen SL; Lee SY; Tao PL; Chang YH; Chen SH; Chu CH; Chen PS; Lee IH; Yeh TL; Yang YK; Hong JS; Lu RB
J Neuroimmune Pharmacol; 2012 Dec; 7(4):1025-33. PubMed ID: 22990619
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive memantine for opioid use disorder treatment: A systematic review.
Elias AM; Pepin MJ; Brown JN
J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
[TBL] [Abstract][Full Text] [Related]
8. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
[TBL] [Abstract][Full Text] [Related]
9. Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy.
Chang YH; Chen SL; Lee SY; Chen PS; Wang TY; Lee IH; Chen KC; Yang YK; Hong JS; Lu RB
Sci Rep; 2015 May; 5():9708. PubMed ID: 25989606
[TBL] [Abstract][Full Text] [Related]
10. The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment.
Ghaderi A; Banafshe HR; Mirhosseini N; Motmaen M; Mehrzad F; Bahmani F; Aghadavod E; Mansournia MA; Reiter RJ; Karimi MA; Asemi Z
Addict Biol; 2019 Jul; 24(4):754-764. PubMed ID: 29949232
[TBL] [Abstract][Full Text] [Related]
11. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial.
Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang YS; Wang LJ; Lee IH; Wang TY; Yeh TL; Yang YK; Hong JS; Lu RB
J Clin Psychopharmacol; 2014 Jun; 34(3):337-43. PubMed ID: 24717258
[TBL] [Abstract][Full Text] [Related]
12. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.
de Lucena D; Fernandes BS; Kunz M; Fries GR; Stertz L; Aguiar B; Pfaffenseller B; Gama CS
J Clin Psychiatry; 2010 Jan; 71(1):91-2. PubMed ID: 20129011
[No Abstract] [Full Text] [Related]
14. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
Belcher AM; Cole TO; Greenblatt AD; Hoag SW; Epstein DH; Wagner M; Billing AS; Massey E; Hamilton KR; Kozak ZK; Welsh CJ; Weintraub E; Wickwire EM; Wish ED; Kaptchuk TJ; Colloca L
BMJ Open; 2019 Jun; 9(6):e026604. PubMed ID: 31230007
[TBL] [Abstract][Full Text] [Related]
15. Rosa Damascena oil improved methadone-related sexual dysfunction in females with opioid use disorder under methadone maintenance therapy - results from a double-blind, randomized, and placebo-controlled trial.
Farnia V; Tatari F; Alikhani M; Yazdchi K; Taghizadeh M; Sadeghi Bahmani D; Karbasizadeh H; Holsboer-Trachsler E; Brand S
J Psychiatr Res; 2017 Dec; 95():260-268. PubMed ID: 28923720
[TBL] [Abstract][Full Text] [Related]
16. Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use.
Carroll KM; DeVito EE; Yip SW; Nich C; Sofuoglu M
Am J Addict; 2019 Jul; 28(4):238-245. PubMed ID: 31165574
[TBL] [Abstract][Full Text] [Related]
17. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.
Oliveto A; Poling J; Mancino MJ; Feldman Z; Cubells JF; Pruzinsky R; Gonsai K; Cargile C; Sofuoglu M; Chopra MP; Gonzalez-Haddad G; Carroll KM; Kosten TR
Drug Alcohol Depend; 2011 Jan; 113(2-3):184-91. PubMed ID: 20828943
[TBL] [Abstract][Full Text] [Related]
19. Add-on memantine may improve cognitive functions and attenuate inflammation in middle- to old-aged bipolar II disorder patients.
Lu RB; Wang TY; Lee SY; Chang YH; Chen SL; Tsai TY; Chen PS; Huang SY; Tzeng NS; Lee IH; Chen KC; Yang YK; Hong JS
J Affect Disord; 2021 Jan; 279():229-238. PubMed ID: 33069121
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review.
Fluyau D; Revadigar N; Pierre CG
Drug Alcohol Depend; 2020 Mar; 208():107845. PubMed ID: 31978670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
